查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800307

全球抗风湿药物市场：未来预测（2025-2030）

Global Anti-Rheumatic Drug Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

抗风湿药物市场预计将从 2025 年的 744.44 亿美元成长到 2030 年的 842 亿美元，复合年增长率为 2.49%。

由于风湿病（尤其是类风湿性关节炎(RA)）盛行率不断上升以及人口老化，抗风湿药物市场正在经历显着增长。这些慢性疾病，包括 RA、干癣性关节炎、红斑性狼疮和骨关节炎，会引起关节、肌肉和骨骼的发炎、疼痛和僵硬，严重影响患者的生活品质。抗风湿药物，包括非类固醇消炎剂(NSAID)、皮质类固醇、缓解疾病的抗风湿生物製药，在控制症状、减轻发炎和预防关节损伤方面发挥重要作用。市场分为药品（化学合成的小分子药物）和生物製剂（使用活生物体或基因工程细胞製造的生技药品），提供多样化的治疗选择。

成长动力

抗风湿药物市场的主要驱动力是风湿病患病率的上升，而全球人口老化则加剧了这一趋势。与老龄化相关的关节软骨劣化会导致疼痛、僵硬和活动能力下降，通常需要抗风湿药物和关节重建等治疗。根据世界卫生组织 (WHO) 的数据，类风湿性关节炎影响全球超过 2,300 万人，女性罹患此病的可能性是男性的三倍。世界银行强调，老化是风湿病患病率上升的一个主要因素，推动了对有效治疗方法的需求。这种人口结构的变化凸显了对药物的需求，以控制症状并改善 RA 和其他自体免疫疾病（如狼疮）患者的生活质量，这些疾病会影响多个器官并引起广泛的发炎。

市场范围及应用

抗风湿药物市场因其在治疗类风湿性关节炎（RA）和干癣性关节炎等自体免疫疾病中的作用而迅速扩张。这些药物透过消炎、止痛和减缓关节损伤的进展来改善患者的预后。除了类风湿性关节炎之外，抗风湿药物在治疗红斑性狼疮方面也扮演重要角色。狼疮是一种免疫系统攻击健康细胞，导致关节、肾臟、心臟和肺部发炎的疾病。这些药物适用于多种自体免疫疾病，既可以缓解症状，又可以进行长期疾病管理，这推动了市场的成长。

地理视角

从区域来看，市场细分为北美、南美、欧洲、中东和非洲以及亚太地区，其中北美，尤其是美国，预计将占据相当大的份额。美国市场的成长主要受到久坐不动、肥胖和不健康的生活习惯等因素的影响，导致关节炎盛行率不断上升。美国疾病管制与预防中心预测，到2030年，将有7,200万美国成年人被医生诊断为关节炎，这将显着增加疾病负担，并增加对抗风湿药物的需求。

技术创新与监管发展

最近的进展包括美国食品药物管理局于 2023 年Janus核准Janus激酶抑制剂，这是一类新型 DMARD，旨在减缓 RA 患者关节损伤的进展。此类创新凸显了该行业在开发标靶治疗的持续努力，进一步推动了市场成长。

摘要，受人口老化、风湿病患病率上升以及抗风湿药物（DMARDs）和生物製药等创新疗法的推动，抗风湿药物市场预计将持续扩张。北美，尤其是美国，由于关节炎患者数量的增加和产品开发的强劲，将继续成为主要的成长地区。

本报告的主要优点

  • 深刻分析：获得深入的市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场驱动因素和未来趋势：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力来提供策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业来说，都是有益且具有成本效益的。

它有什么用途？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024）和预测资料（2025-2030）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按部门和地区（国家）分類的收益成长和预测分析
  • 公司概况（策略、产品、财务资讯、主要趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 细分市场

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 全球抗风湿药物市场（依疾病型态）

  • 介绍
  • 类风湿性关节炎
  • 骨关节炎
  • 干癣性关节炎
  • 痛风
  • 红斑性狼疮（狼疮）
  • 僵直性脊椎炎
  • 其他的

6. 全球抗风湿药物市场（依药物类别）

  • 介绍
  • 缓解疾病的抗风湿药物（DMARDs）
  • 非类固醇消炎剂（NSAID）
  • 皮质类固醇
  • JAK抑制剂
  • 其他的

7. 全球抗风湿药物市场依销售管道

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

8. 全球抗风湿药物市场（按地区）

  • 介绍
  • 北美洲
    • 依疾病类型
    • 按药品类别
    • 按销售管道
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依疾病类型
    • 按药品类别
    • 按销售管道
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 依疾病类型
    • 按药品类别
    • 按销售管道
    • 按国家
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 依疾病类型
    • 按药品类别
    • 按销售管道
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 依疾病类型
    • 按药品类别
    • 按销售管道
    • 按国家
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪表板

第十章：公司简介

  • AbbVie Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • Roche Holding AG
  • GlaxoSmithKline plc

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061613477

The Global Anti-Rheumatic Drug Market is expected to grow from USD 74.444 billion in 2025 to USD 84.200 billion in 2030, at a CAGR of 2.49%.

The global anti-rheumatic drug market is experiencing significant growth, driven by the rising prevalence of rheumatic diseases, particularly rheumatoid arthritis (RA), and an aging population. These chronic conditions, including RA, psoriatic arthritis, lupus, and osteoarthritis, cause inflammation, pain, and stiffness in joints, muscles, and bones, severely impacting patients' quality of life. Anti-rheumatic drugs, encompassing nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic agents, are critical in managing symptoms, reducing inflammation, and preventing joint damage. The market is segmented into pharmaceuticals (chemically synthesized small-molecule drugs) and biopharmaceuticals (biologics produced using living organisms or genetically engineered cells), offering diverse treatment options.

Growth Drivers

The primary driver of the anti-rheumatic drug market is the increasing prevalence of rheumatic diseases, exacerbated by an aging global population. As people age, joint cartilage deteriorates, leading to pain, stiffness, and reduced mobility, often necessitating treatments like anti-rheumatic drugs or joint replacement surgery. According to the World Health Organization, rheumatoid arthritis affects over 23 million people worldwide, with women three times more likely to develop it than men. The World Bank highlights the growing aging population as a key factor increasing the incidence of rheumatic disorders, thereby driving demand for effective therapies. This demographic shift underscores the need for drugs that manage symptoms and improve quality of life for patients with RA and other autoimmune diseases like lupus, which affects multiple organs and causes widespread inflammation.

Market Scope and Applications

The anti-rheumatic drug market is expanding rapidly due to its role in treating autoimmune conditions such as RA and psoriatic arthritis. These drugs reduce inflammation, alleviate pain, and slow joint damage progression, enhancing patient outcomes. Beyond RA, anti-rheumatic drugs are vital for managing lupus, where the immune system attacks healthy cells, leading to inflammation in joints, kidneys, heart, and lungs. The versatility of these drugs across various autoimmune diseases fuels market growth, as they address both symptom relief and long-term disease management.

Geographical Outlook

Geographically, the market is divided into North America, South America, Europe, the Middle East and Africa, and Asia Pacific, with North America, particularly the United States, expected to hold a significant share. The U.S. market is driven by rising arthritis prevalence, attributed to factors like sedentary lifestyles, obesity, and poor health habits. The Centers for Disease Control and Prevention projects that by 2030, 72 million U.S. adults will have doctor-diagnosed arthritis, reflecting a significant increase in disease burden and demand for anti-rheumatic drugs.

Innovations and Regulatory Developments

Recent advancements include the U.S. Food and Drug Administration's approval of Janus Kinase Inhibitors in January 2023, a new class of DMARDs designed to slow joint damage progression in RA patients. Such innovations highlight ongoing industry efforts to develop targeted therapies, further propelling market growth.

In summary, the anti-rheumatic drug market is poised for continued expansion, driven by an aging population, rising rheumatic disease prevalence, and innovative treatments like DMARDs and biologics. North America, particularly the U.S., remains a key growth region due to increasing arthritis cases and robust product development.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Type Of Disease

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Gout
  • Lupus
  • Ankylosing Spondylitis
  • Others

By Drug Class

  • Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • JAK inhibitor
  • Others

By Sales Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • South America
  • Europe
  • Middle East and Africa
  • Asia Pacific

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY TYPE OF DISEASE

  • 5.1. Introduction
  • 5.2. Rheumatoid Arthritis
  • 5.3. Osteoarthritis
  • 5.4. Psoriatic Arthritis
  • 5.5. Gout
  • 5.6. Lupus
  • 5.7. Ankylosing Spondylitis
  • 5.8. Others

6. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY DRUG CLASS

  • 6.1. Introduction
  • 6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • 6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 6.4. Corticosteroids
  • 6.5. JAK inhibitor
  • 6.6. Others

7. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY SALES CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies
  • 7.4. Online Pharmacies

8. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type of Disease
    • 8.2.2. By Drug Class
    • 8.2.3. By Sales Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type of Disease
    • 8.3.2. By Drug Class
    • 8.3.3. By Sales Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type of Disease
    • 8.4.2. By Drug Class
    • 8.4.3. By Sales Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type of Disease
    • 8.5.2. By Drug Class
    • 8.5.3. By Sales Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type of Disease
    • 8.6.2. By Drug Class
    • 8.6.3. By Sales Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. AbbVie Inc.
  • 10.2. Pfizer Inc.
  • 10.3. Johnson & Johnson
  • 10.4. Amgen Inc.
  • 10.5. Novartis AG
  • 10.6. Eli Lilly and Company
  • 10.7. Bristol Myers Squibb
  • 10.8. Merck & Co., Inc.
  • 10.9. Roche Holding AG
  • 10.10. GlaxoSmithKline plc

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations